# A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

> **NCT01275170** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 49 (actual)

## Conditions studied

- Infectious Disease

## Interventions

- **DRUG:** MK-7655
- **DRUG:** Imipenem + Cilastatin
- **DRUG:** Caffeine
- **DRUG:** Midazolam
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT01275170
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-28
- **Primary completion:** 2012-03-05
- **Final completion:** 2012-03-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275170, "A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01275170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*